Mealey's (April 2, 2019, 8:28 AM EDT) -- WASHINGTON, D.C. — The U.S. Federal Trade Commission on March 29 announced that it voted 5-0 that Impax Laboratories LLC engaged in an illegal pay-for-delay or “reverse payment” settlement with Endo Pharmaceuticals Inc. to block Impax from selling a lower-cost generic version of Impax’s opioid drug Opana ER....